Page 72 - IMO-2-3

Innovative Medicines & Omics Peganum harmala and GLP-1: A natural approach

Availability of data 11. Yi T, Li X, Wang E, et al. Activation of the nuclear erythroid
2-related factor 2 antioxidant responsive element (Nrf2-ARE)
Not applicable. signaling pathway alleviates acute graft-versus-host disease
by reducing oxidative stress and inhibiting infiltration of
References inflammatory cells in an allogeneic stem cell transplantation
1. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide mouse model. Med Sci Monit. 2018;24:5973-5979.
1 (GLP-1). Mol Metab. 2019;30:72-130. doi: 10.12659/MSM.908130
doi: 10.1016/j.molmet.2019.09.010 12. Chen X, Guo C, Kong J. Oxidative stress in neurodegenerative
2. Nadkarni P, Chepurny OG, Holz GG. Regulation of glucose diseases. Neural Regen Res. 2012;7(5):376-385.
homeostasis by GLP-1. Prog Mol Biol Transl Sci. 2014;121:23-65. doi: 10.3969/j.issn.1673-5374.2012.05.009

doi: 10.1016/B978-0-12-800101-1.00002-8 13. Jeong WS, Jun M, Kong AN. Nrf2: A potential molecular
3. Diz-Chaves Y, Maastor Z, Spuch C, Lamas JA, González- target for cancer chemoprevention by natural compounds.
Matías LC, Mallo F. Glucagon-like peptide 1 receptor Antioxid Redox Signal. 2006;8(1-2):99-106.
activation: Anti-inflammatory effects in the brain. Neural doi: 10.1089/ars.2006.8.99
Regen Res. 2024;19(8):1671-1677.
14. Jain S, Panuganti V, Jha S, Roy I. Harmine acts as an indirect
doi: 10.4103/1673-5374.389626 inhibitor of intracellular protein aggregation. ACS Omega.
4. Kalinderi K, Papaliagkas V, Fidani L. GLP-1 receptor 2020;5(11):5620-5628.
agonists: A new treatment in Parkinson’s disease. Int J Mol doi: 10.1021/acsomega.9b02375
Sci. 2024;25(7):3812.
15. Jiang Y, Bao H, Ge Y, et al. Therapeutic targeting of GSK3β
doi: 10.3390/ijms25073812 enhances the Nrf2 antioxidant response and confers hepatic
5. Moloudizargari M, Mikaili P, Aghajanshakeri S, Asghari MH, cytoprotection in hepatitis C. Gut. 2015;64(1):168-179.
Shayegh J. Pharmacological and therapeutic effects of doi: 10.1136/gutjnl-2013-306043
Peganum harmala and its main alkaloids. Pharmacogn Rev.
2013;7(14):199-212. 16. Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1
receptor: Mechanisms and advances in therapy. Signal
doi: 10.4103/0973-7847.120524 Transduct Target Ther. 2024;9:234.
6. Berlowitz I, Egger K, Cumming P. Monoamine oxidase doi: 10.1038/s41392-024-01931-z
inhibition by plant-derived β-carbolines; Implications for
the psychopharmacology of tobacco and ayahuasca. Front 17. Smith NK, Hackett TA, Galli A, Flynn CR. GLP-1: Molecular
Pharmacol. 2022;13:886408. mechanisms and outcomes of a complex signaling system.
Neurochem Int. 2019;128:94-105.
doi: 10.3389/fphar.2022.886408
doi: 10.1016/j.neuint.2019.04.010
7. Saleh RA, Eissa TF, Abdallah DM, Saad MA, El-Abhar HS.
Peganum harmala enhanced GLP-1 and restored insulin 18. Doyle ME, Egan JM. Mechanisms of action of glucagon-like
signaling to alleviate AlCl -induced Alzheimer-like peptide 1 in the pancreas. Pharmacol Ther. 2007;113(3):546-593.
3
pathology model. Sci Rep. 2021;11(1):12040. doi: 10.1016/j.pharmthera.2006.11.007
doi: 10.1038/s41598-021-90545-4 19. Kaneto H, Kimura T, Shimoda M, et al. Favorable effects
8. Świderska E, Strycharz J, Wróblewski A, Szemraj J, of GLP-1 receptor agonist against pancreatic β-cell glucose
Drzewoski J, Śliwińska A. Role of PI3K/AKT Pathway in toxicity and the development of arteriosclerosis: “The
Insulin-Mediated Glucose Uptake. London: IntechOpen; 2020. earlier, the better” in therapy with incretin-based medicine.
Int J Mol Sci. 2021;22(15):7917.
doi: 10.5772/intechopen.80402
doi: 10.3390/ijms22157917
9. Rupprecht LE, Mietlicki-Baase EG, Zimmer DJ, McGrath LE,
Olivos DR, Hayes MR. Hindbrain GLP-1 receptor-mediated 20. Diz-Chaves Y, Herrera-Pérez S, González-Matías LC,
suppression of food intake requires a PI3K-dependent Lamas JA, Mallo F. Glucagon-like peptide-1 (GLP-1) in
decrease in phosphorylation of membrane-bound Akt. Am J the integration of neural and endocrine responses to stress.
Physiol Endocrinol Metab. 2013;305(6):E751-E759. Nutrients. 2020;12(11):3304.
doi: 10.1152/ajpendo.00367.2013 doi: 10.3390/nu12113304
10. Tunduguru R, Thurmond DC. Promoting glucose 21. Camilleri M. Gastrointestinal hormones and regulation of
transporter-4 vesicle trafficking along cytoskeletal tracks: gastric emptying. Curr Opinion Endocrinol Diabetes Obes.
PAK-Ing them out. Front Endocrinol (Lausanne). 2017;8:329. 2019;26(1):3-10.
doi: 10.3389/fendo.2017.00329 doi: 10.1097/MED.0000000000000448

Volume 2 Issue 3 (2025) 66 doi: 10.36922/IMO025060009